Institut de Pharmacologie et Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, 205 Route de Narbonne, BP64182, 31077 Toulouse, France.
Nanoscale. 2019 Feb 14;11(7):3248-3260. doi: 10.1039/c8nr10249j.
The development of drug delivery and imaging tools is a major challenge in human health, in particular in cancer pathologies. This work describes the optimization of a protein nanocontainer, belonging to the lectin protein family, for its use in epithelial cancer diagnosis and treatment. Indeed, it specifically targets a glycosidic marker, the T antigen, which is known to be characteristic of epithelial cancers. Its quaternary structure reveals a large hydrated inner cavity able to transport small therapeutic molecules. Optimization of the nanocontainer by site directed mutagenesis allowed controlling loading and release of confined drugs. Doxorubicin confinement was followed, both theoretically and experimentally, and provided a proof of concept for the use of this nanocontainer as a vectorization system. In OVCAR-3 cells, a human ovarian adenocarcinoma cell line that expresses the T antigen, the drug was observed to be delivered inside late endosomes/lysosomes. These results show that this new type of vectorization and imaging device opens new exciting perspectives in nano-theranostic approaches.
药物输送和成像工具的发展是人类健康的主要挑战,特别是在癌症病理方面。本工作描述了一种蛋白质纳米容器的优化,该蛋白质纳米容器属于凝集素蛋白家族,用于上皮性癌症的诊断和治疗。事实上,它专门针对糖基标记物 T 抗原,该抗原是上皮性癌症的特征。其四级结构显示出一个大的水合内腔,能够运输小分子治疗药物。通过定点突变对纳米容器进行优化,可控制所包含药物的装载和释放。阿霉素的包封情况进行了理论和实验研究,为将这种纳米容器用作载体系统提供了概念验证。在表达 T 抗原的人卵巢腺癌细胞系 OVCAR-3 中,观察到药物被递送到晚期内体/溶酶体中。这些结果表明,这种新型载体化和成像装置为纳米治疗学方法开辟了新的令人兴奋的前景。